民族植物学和实验室数据能否预测抗疟植物的临床安全性和疗效？
Do ethnobotanical and laboratory data predict clinical safety and efficacy of anti-malarial plants?
机构信息
Research Initiative on Traditional Antimalarial Methods, 66 Lye Valley, Oxford OX3 7ER, UK.
出版信息
Malar J. 2011 Mar 15;10 Suppl 1(Suppl 1):S7. doi: 10.1186/1475-2875-10-S1-S7.
BACKGROUND
Over 1200 plant species are reported in ethnobotanical studies for the treatment of malaria and fevers, so it is important to prioritize plants for further development of anti-malarials.
METHODS
The "RITAM score" was designed to combine information from systematic literature searches of published ethnobotanical studies and laboratory pharmacological studies of efficacy and safety, in order to prioritize plants for further research. It was evaluated by correlating it with the results of clinical trials.
RESULTS AND DISCUSSION
The laboratory efficacy score correlated with clinical parasite clearance (rs=0.7). The ethnobotanical component correlated weakly with clinical symptom clearance but not with parasite clearance. The safety component was difficult to validate as all plants entering clinical trials were generally considered safe, so there was no clinical data on toxic plants.
CONCLUSION
The RITAM score (especially the efficacy and safety components) can be used as part of the selection process for prioritising plants for further research as anti-malarial drug candidates. The validation in this study was limited by the very small number of available clinical studies, and the heterogeneity of patients included.
背景
在针对疟疾和发热的民族植物学研究中，有超过 1200 种植物被报道具有治疗作用，因此优先选择植物进行抗疟药物开发非常重要。
方法
“RITAM 评分”旨在结合已发表的民族植物学研究的系统文献检索和实验室药效学及安全性研究的信息，以便优先选择进一步研究的植物。通过与临床试验结果进行相关性分析来评估该评分。
结果与讨论
实验室药效学评分与临床寄生虫清除率相关（rs=0.7）。民族植物学成分与临床症状清除率弱相关，但与寄生虫清除率无关。由于所有进入临床试验的植物通常被认为是安全的，因此安全性成分难以验证，因此没有关于有毒植物的临床数据。
结论
RITAM 评分（尤其是药效学和安全性成分）可作为选择进一步研究作为抗疟药物候选物的植物的优先顺序的选择过程的一部分。本研究的验证受到可用临床研究数量较少和纳入患者异质性的限制。
Zotero 插件